Evaxion Biotech A/S (EVAX) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
EVAX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
EVAX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 99.7% | -122.7% | -102.4% |
| 2024 | 100.0% | -440.6% | -316.0% |
| 2023 | 100.0% | -30406.8% | -30308.2% |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export EVAX earnings history in CSV or JSON format
Free sign-in required to download data
Evaxion Biotech A/S (EVAX) Earnings Overview
As of May 8, 2026, Evaxion Biotech A/S (EVAX) reported trailing twelve-month net income of -$8M, reflecting +87.7% year-over-year growth. The company earned $-1.21 per diluted share over the past four quarters, with a net profit margin of -102.4%.
Looking at the long-term picture, EVAX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2018.
Evaxion Biotech A/S is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NEON ($8M net income, 411.9% margin), IMVT (-$464M net income), NKTR (-$164M net income, -297.1% margin), EVAX has room to improve margins relative to the peer group. Compare EVAX vs NEON →
EVAX Earnings vs Peers
Earnings metrics vs comparable public companies
EVAX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | +26.8% | -$9M | $-1.21 | -102.4% | -122.7% |
| 2024 | -$11M | +52.2% | -$15M | $-9.80 | -316.0% | -440.6% |
| 2023 | -$22M | +4.5% | -$22M | $-32.40 | -30308.2% | -30406.8% |
| 2022 | -$23M | +5.6% | -$25M | $-39.20 | - | - |
| 2021 | -$25M | -63.4% | -$26M | $-50.40 | - | - |
| 2020 | -$15M | -34.2% | -$17M | $-37.00 | - | - |
| 2019 | -$11M | -102.2% | -$11M | $-27.60 | - | - |
| 2018 | -$6M | - | -$6M | $-11.52 | - | - |
See EVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVAX — Frequently Asked Questions
Quick answers to the most common questions about buying EVAX stock.
Is EVAX growing earnings?
EVAX EPS is $-1.21, with earnings growth accelerating to +87.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-8M.
What are EVAX's profit margins?
Evaxion Biotech A/S net margin is -102.4%, with operating margin at -122.7%. Below-average margins reflect competitive or cost pressures.
How consistent are EVAX's earnings?
EVAX earnings data spans 2018-2025. The accelerating earnings trend is +87.7% YoY. Historical data enables comparison across business cycles.